Table 2 Enriched canonical pathways of the differentially expressed genes using Ingenuity Pathway Analysis (IPA) software for insulin, high fat and high fat/insulin treatments
| Â | -log (p-value) | Ratio | z-score |
|---|---|---|---|
Insulin | |||
 Calcium signaling | 7.98 | 2.12E-01 | -0.426 |
 p53 signaling | 5.00 | 2.16E-01 | 0.218 |
 Signaling by Rho Family GTPases | 4.72 | 1.63E-01 | 0.324 |
 Superpathway of inositol phosphate compounds | 4.62 | 1.67E-01 | 0.000 |
 B cell receptor signaling | 4.56 | 1.76E-01 | -1.095 |
High fat | |||
 Calcium signaling | 9.77 | 2.37E-01 | 0.557 |
 Amyloid process | 5.52 | 3.20E-01 | 0.000 |
 B cell receptor signaling | 5.25 | 1.91E-01 | -0.690 |
 Role of NFAT in cardiac hypertrophy | 4.62 | 1.76E-01 | -0.822 |
 GNRH signalling | 4.60 | 1.91E-01 | -1.633 |
 Protein kinase A signalling | 4.28 | 1.48E-01 | -1.342 |
 PI3k signaling in B lymphocytes | 4.10 | 1.98E-01 | -1.400 |
 Type II diabetes mellitus signalling | 3.17 | 1.71E-01 | 0.000 |
 AMPK signaling | 2.15 | 1.40E-01 | -0.626 |
High fat insulin | |||
 RANK signaling in osteoclasts | 4.68 | 2.20E-01 | -0.447 |
 Antioxidant action of vitamin C | 3.92 | 2.02E-01 | -1.886 |
 IL-6 signaling | 3.86 | 1.88E-01 | 0.000 |
 April mediated signaling | 3.61 | 2.82E-01 | -1.508 |
 CD27 signaling in lymphocytes | 3.58 | 2.50E-01 | 0.000 |
 NF-κB signaling | 3.42 | 1.63E-01 | -0.186 |
 B Cell activating factor signaling | 3.40 | 2.68E-01 | -1.265 |
 Type I diabetes mellitus signaling | 3.30 | 1.87E-01 | -2.357 |
 Role of NFAT in cardiac hypertrophy | 3.29 | 1.53E-01 | 2.121 |
 IL-4 signaling | 3.18 | 1.98E-01 | 0.000 |